{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:32:12Z","timestamp":1789144332093,"version":"build-2803163510"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Myelodysplastic Neoplasms (MDS) are a group of clonal hematopoietic malignancies originating from hematopoietic stem cells. Their pathogenesis involves not only genetic abnormalities in hematopoietic cells but is also closely associated with functional dysregulation of the bone marrow microenvironment (BMME). In MDS, both the heterogeneous cellular populations and non-cellular components of the BMME exhibit significant dysfunction. Aberrant BMME components drive the initiation and progression of the disease through complex intercellular interactions. In-depth research into its pathological features and molecular mechanisms is of great significance for developing effective targeted therapeutic strategies. In recent years, novel treatment strategies based on BMME regulation have made significant progress, including immunomodulators, epigenetic regulators, molecularly targeted drugs, and cell therapies, providing new insights for improving the clinical outcomes of MDS patients. This article systematically reviews the pathological features of the BMME in MDS and its key molecular mechanisms in disease development, and discusses the latest clinical research advances in BMME-targeted therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1726707","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:46:39Z","timestamp":1771915599000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Bone marrow microenvironment reprogramming in myelodysplastic neoplasms: from pathological mechanisms to targeted therapeutic strategies"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaofei","family":"Cong","sequence":"first","affiliation":[{"name":"Department of Hematology, Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohuan","family":"Peng","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.leukres.2018.07.019","article-title":"The IPSS-R has prognostic impact in untreated patients with MDS del(5q)","volume":"72","author":"Kaivers","year":"2018","journal-title":"Leukemia Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164116","article-title":"Nature or nurture? Role of the bone marrow microenvironment in the genesis and maintenance of myelodysplastic syndromes","volume":"13","author":"Mian","year":"2021","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41556-019-0439-6","article-title":"Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization","volume":"22","author":"Baccin","year":"2020","journal-title":"Nat Cell Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/intimm\/dxy058","article-title":"Niches for hematopoietic stem cells and immune cell progenitors","volume":"31","author":"Sugiyama","year":"2019","journal-title":"Int Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1038\/s41467-018-04726-3","article-title":"Stem cell factor is selectively secreted by arterial endothelial cells in bone marrow","volume":"9","author":"Xu","year":"2018","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00258","article-title":"Senescence in mesenchymal stem cells: functional alterations, molecular mechanisms, and rejuvenation strategies","volume":"8","author":"Liu","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186734","article-title":"Transforming growth factor \u03b21-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia","volume":"103","author":"Geyh","year":"2018","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41419-023-06197-x","article-title":"MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes","volume":"14","author":"Giallongo","year":"2023","journal-title":"Cell Death Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/0963689717745890","article-title":"Aging- and senescence-associated changes of mesenchymal stromal cells in myelodysplastic syndromes","volume":"27","author":"Mattiucci","year":"2018","journal-title":"Cell Transplant"},{"key":"B10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41419-018-0545-6","article-title":"Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells","volume":"9","author":"Guo","year":"2018","journal-title":"Cell Death Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110805","article-title":"MDS cells impair osteolineage differentiation of MSCs via extracellular vesicles to suppress normal hematopoiesis","volume":"39","author":"Hayashi","year":"2022","journal-title":"Cell Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/1574888X12666171012141908","article-title":"PPAR-\u03b3 and wnt regulate the differentiation of MSCs into adipocytes and osteoblasts respectively","volume":"13","author":"Li","year":"2018","journal-title":"Curr Stem Cell Res Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.172726","article-title":"Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical wnt pathway","volume":"103","author":"Balaian","year":"2018","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.ccell.2025.03.007","article-title":"A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid Malignancies","volume":"43","author":"Mosialou","year":"2025","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.989483","article-title":"The genetics of myelodysplastic syndromes and the opportunities for tailored treatments","volume":"12","author":"Kontandreopoulou","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.1038\/s41467-021-26424-3","article-title":"Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo","volume":"12","author":"Jann","year":"2021","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12935-019-0855-5","article-title":"Ally to adversary: mesenchymal stem cells and their transformation in leukaemia","volume":"19","author":"Sharma","year":"2019","journal-title":"Cancer Cell Int"},{"key":"B18","article-title":"Notch-hes pathway mediates the impaired osteogenic differentiation of bone marrow mesenchymal stromal cells from myelodysplastic syndromes patients through the down-regulation of Runx2","volume":"7","author":"Fei","year":"2015","journal-title":"Am J Trans Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0267-x","article-title":"Activation of NF-\u03baB driven inflammatory programs in mesenchymal elements attenuates hematopoiesis in low-risk myelodysplastic syndromes","volume":"33","author":"Ping","year":"2019","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1639439","DOI":"10.3389\/fbioe.2025.1639439","article-title":"From bench to bedside: translating mesenchymal stem cell therapies through preclinical and clinical evidence","volume":"13","author":"Patel","year":"2025","journal-title":"Front Bioeng Biotechnol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1078421","DOI":"10.3389\/fimmu.2022.1078421","article-title":"The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231183330","article-title":"Immune dysregulation and potential targeted therapy in myelodysplastic syndrome","volume":"14","author":"Zhang","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.617466","article-title":"Senescent mesenchymal stem cells in myelodysplastic syndrome: functional alterations, molecular mechanisms, and therapeutic strategies","volume":"8","author":"Chen","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.exphem.2015.10.005","article-title":"Impairment of PI3K\/AKT and WNT\/\u03b2-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes","volume":"44","author":"Falconi","year":"2016","journal-title":"Exp Hematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3978\/j.issn.2306-9759.2014.08.02","article-title":"Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes","volume":"1","author":"Wang","year":"2014","journal-title":"Stem Cell Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0267-x","article-title":"Activation of NF-\u03baB driven inflammatory programs in mesenchymal elements attenuates hematopoiesis in low-risk myelodysplastic syndromes","volume":"33","author":"Ping","year":"2019","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7534\/j.issn.1009-2137.2016.01.056","article-title":"Bone marrow microenvironment and myelodysplastic syndromes\u2013review","volume":"24","author":"Zhang","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2016.0295","article-title":"Alteration analysis of bone marrow mesenchymal stromal cells from de novo acute myeloid leukemia patients at diagnosis","volume":"26","author":"Desbourdes","year":"2017","journal-title":"Stem Cells Dev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18748","article-title":"Turning the spotlight on bone marrow adipocytes in haematological malignancy and non-malignant conditions","volume":"201","author":"Austin","year":"2023","journal-title":"Br J Haematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-024-00879-x","article-title":"Molecular deconvolution of bone marrow adipose tissue interactions with malignant hematopoiesis: potential for new therapy development","volume":"22","author":"Trivanovi\u0107","year":"2024","journal-title":"Curr Osteoporos Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/\u03b2-catenin signaling, disease, and emerging therapeutic modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3892\/ol.2023.13681","article-title":"Evaluation of VEGF and VEGFR gene expression as prognostic markers in low and intermediate\u20111 risk patients with myelodysplastic syndromes","volume":"25","author":"Kalitin","year":"2023","journal-title":"Oncol Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.642352","article-title":"Notch signaling in vascular endothelial cells, angiogenesis, and tumor progression: an update and prospective","volume":"9","author":"Akil","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404590","article-title":"Prevalence and clinical association of clonal T-cell expansions in myelodysplastic syndrome","volume":"21","author":"Epling-Burnette","year":"2007","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1046\/j.1365-2141.2002.03802.x","article-title":"Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome","volume":"119","author":"Melenhorst","year":"2002","journal-title":"Br J Haematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948362","article-title":"CD28 and CD57 define four populations with distinct phenotypic properties within human CD8+ T cells","volume":"50","author":"Pangrazzi","year":"2020","journal-title":"Eur J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-277921","article-title":"T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy","volume":"117","author":"Sloand","year":"2011","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9404705","article-title":"Th17 cells exhibit antitumor effects in MDS possibly through augmenting functions of CD8+ T cells","volume":"2016","author":"Li","year":"2016","journal-title":"J Immunol Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15496","article-title":"Reduced regulatory T cells (Treg) in bone marrow preferentially associate with the expansion of cytotoxic T lymphocytes in low risk MDS patients","volume":"185","author":"Giovazzino","year":"2019","journal-title":"Br J Haematol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn.1009-2137.2023.02.023","article-title":"The distribution and significance of activated T cells and lymphocyte subsets in myelodysplastic syndrome","volume":"31","author":"Hu","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B42","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/ejh.13822","article-title":"Bone marrow CD3+ CD56+ regulatory T lymphocytes (TR3-56 cells) are inversely associated with activation and expansion of bone marrow cytotoxic T cells in IPSS-R very-low\/low risk MDS patients","volume":"109","author":"Leone","year":"2022","journal-title":"Eur J Haematol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"Zhu B","volume":"6","author":"Jiang","year":"2015","journal-title":"T-cell exhaustion tumor microenvironment. Cell Death Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes","volume":"110","author":"Pang","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5479013","article-title":"Monocyte-derived macrophages are impaired in myelodysplastic syndrome","volume":"2016","author":"Han","year":"2016","journal-title":"J Immunol Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9913382","article-title":"Abnormal macrophage polarization in patients with myelodysplastic syndrome","volume":"2021","author":"Zhang","year":"2021","journal-title":"Mediators Inflamm"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143180","article-title":"Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner","volume":"101","author":"Al-Matary","year":"2016","journal-title":"Haematologica"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121526","article-title":"Tumor-associated macrophages in hematologic malignancies: new insights and targeted therapies","volume":"8","author":"Petty","year":"2019","journal-title":"Cells"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404080","article-title":"Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes","volume":"20","author":"Kiladjian","year":"2006","journal-title":"Leukemia"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.149","article-title":"Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome","volume":"24","author":"Carlsten","year":"2010","journal-title":"Leukemia"},{"key":"B51","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41467-023-36193-w","article-title":"Myelodysplastic syndrome associated TET2 mutations affect NK cell function and genome methylation","volume":"14","author":"Boy","year":"2023","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1097\/HS9.0000000000000335","article-title":"Abnormal dendritic cell-poiesis in patients with lower-risk myelodysplastic syndromes","volume":"4","author":"S\u00e1nchez","year":"2020","journal-title":"Hemasphere"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.51","article-title":"Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy","volume":"5","author":"Kerkhoff","year":"2013","journal-title":"Immunotherapy"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164908","article-title":"Myeloid-derived suppressor cells: new insights into the pathogenesis and therapy of MDS","volume":"11","author":"Velegraki","year":"2022","journal-title":"J Clin Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225656","article-title":"Bone marrow immune microenvironment in myelodysplastic syndromes","volume":"14","author":"Kouroukli","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84431","article-title":"HIF1\u03b1 and metabolic reprogramming in inflammation","volume":"126","author":"Corcoran","year":"2016","journal-title":"J Clin Invest"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2010.07.011","article-title":"The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche","volume":"7","author":"Simsek","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011250","article-title":"Myelodysplastic syndromes and metabolism","volume":"22","author":"Balaian","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B59","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s11658-024-00570-0","article-title":"Role of reactive oxygen species in myelodysplastic syndromes","volume":"29","author":"Jing","year":"2024","journal-title":"Cell Mol Biol Lett"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.696637","article-title":"Hypoxia-inducible factor-1\u03b1 expression indicates poor prognosis in myelodysplastic syndromes","volume":"53","author":"Tong","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B61","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1158\/2159-8290.CD-21-0218","article-title":"Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability","volume":"13","author":"Thomas","year":"2023","journal-title":"Cancer Discovery"},{"key":"B62","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40164-022-00309-7","article-title":"Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia","volume":"11","author":"Qiao","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123520","article-title":"Bioenergetic profiling of the differentiating human MDS myeloid lineage with low and high bone marrow blast counts","volume":"12","author":"Poulaki","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026135","article-title":"Genetic iron overload aggravates, and pharmacological iron restriction improves, MDS pathophysiology in a preclinical study","volume":"145","author":"Antypiuk","year":"2025","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3529","article-title":"The mitochondrial respiratory chain is essential for haematopoietic stem cell function","volume":"19","author":"Ans\u00f3","year":"2017","journal-title":"Nat Cell Biol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.stem.2012.11.022","article-title":"Metabolic regulation by the mitochondrial phosphatase PTPMT1 is required for hematopoietic stem cell differentiation","volume":"12","author":"Yu","year":"2013","journal-title":"Cell Stem Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.05.017","article-title":"The development of small-molecule inhibitors targeting hexokinase 2","volume":"27","author":"Shan","year":"2022","journal-title":"Drug Discovery Today"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41467-022-28737-3","article-title":"The glycolytic gatekeeper PDK1 defines different metabolic states between genetically distinct subtypes of human acute myeloid leukemia","volume":"13","author":"Erdem","year":"2022","journal-title":"Nat Commun"},{"key":"B69","doi-asserted-by":"publisher","first-page":"6289","DOI":"10.1038\/s41598-018-24676-6","article-title":"The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations","volume":"8","author":"O'Connor","year":"2018","journal-title":"Sci Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2012.06.006","article-title":"Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox","volume":"53","author":"Kikuchi","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"B71","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-019-0617-3","article-title":"The functional mechanisms of mutations in myelodysplastic syndrome","volume":"33","author":"Nagata","year":"2019","journal-title":"Leukemia"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012302","article-title":"Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed\/refractory myelodysplastic syndrome","volume":"8","author":"DiNardo","year":"2024","journal-title":"Blood Adv"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00292-7","article-title":"Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial","volume":"10","author":"Watts","year":"2023","journal-title":"Lancet Haematol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008378","article-title":"Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome","volume":"7","author":"DiNardo","year":"2023","journal-title":"Blood Adv"},{"key":"B75","article-title":"Systematic review of epigenetic targets in acute myeloid leukemia","volume":"11","author":"Verma","year":"2021","journal-title":"Am J Blood Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1002\/hem3.41","article-title":"Luspatercept: a peaceful revolution in the standard of care for myelodysplastic neoplasms","volume":"8","author":"Vinchi","year":"2024","journal-title":"HemaSphere"},{"key":"B78","doi-asserted-by":"publisher","first-page":"eade2774","DOI":"10.1126\/scitranslmed.ade2774","article-title":"Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML","volume":"16","author":"Wheeler","year":"2024","journal-title":"Sci Transl Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10108","article-title":"Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes","volume":"70","author":"Boudard","year":"2002","journal-title":"Am J Hematol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26209859","article-title":"Targeting the BCL2 family: advances and challenges in BH3 mimetic-based therapies","volume":"26","author":"Mukherjee","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01696-4","article-title":"Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy","volume":"28","author":"Ganan-Gomez","year":"2022","journal-title":"Nat Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resistance (Alhambra Calif.)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/bjh.19193","article-title":"Phase 1\/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents","volume":"204","author":"Montalban-Bravo","year":"2024","journal-title":"Br J Haematol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00090-X","article-title":"CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study","volume":"10","author":"Peterlin","year":"2023","journal-title":"Lancet Haematol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial","volume":"7","author":"Othman","year":"2023","journal-title":"Blood Adv"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221112899","article-title":"The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype","volume":"13","author":"Snow","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML","volume":"35","author":"Sekeres","year":"2021","journal-title":"Leukemia"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054708","article-title":"The role of BCL-2 and PD-1\/PD-L1 pathway in pathogenesis of myelodysplastic syndromes","volume":"24","author":"Kuszczak","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B90","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3724\/abbs.2023015","article-title":"S100a9 deficiency accelerates MDS-associated tumor escape via PD-1\/PD-L1 overexpression","volume":"55","author":"Wang","year":"2023","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00263-4","article-title":"Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia","volume":"11","author":"Yang","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105837","article-title":"PD-1\/PD-L1, MDSC pathways, and checkpoint inhibitor therapy in ph(-) myeloproliferative neoplasm: a review","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17689","article-title":"Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome","volume":"195","author":"Chien","year":"2021","journal-title":"Br J Haematol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06511-9","article-title":"CD300ld on neutrophils is required for tumour-driven immune suppression","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1726707\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:46:43Z","timestamp":1771915603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1726707\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":94,"alternative-id":["10.3389\/fimmu.2026.1726707"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1726707","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"1726707"}}